Docetaxel is considered the standard of care in first line for metastatic Castration Resistant Prostate Cancer however over the last decade 5 new agents have demonstrated to prolong survival in the same setting (Cabazitaxel, Sipuleucel-T, Abiraterone Acetate, Enzalutamide, Radium 223), the introduction of such therapeutic options into the routine clinical practice has significantly improved patients prognosis and has totally changed the management of the disease. Currently there are not prospective data about the best sequential strategy hence the oncologist has to choose on the basis of patients characteristics and his own experience with the drug; furthermore the patients, we routinely see in our clinics, significantly differ from the clinical trials population that is typically compliant and in good clinical condition. In this context the ‘real life’ studies, which offer a realistic scenario of our daily practice, have become more and more valuable, we tried to summarize the data emerged from these studies, available only for some of the above mentioned new agents, to identify a potential, ‘ideal’ sequence of treatment for patients with mCRPC. There are not enough evidences to define an exact sequence but this paper highlight several aspects which may help the clinician to decide the best therapeutic approach.